keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/29772084/switching-to-tenofovir-vs-continuing-entecavir-for-hbv-with-partial-virologic-response-to-entecavir-a-randomized-controlled-trial
#1
Hyung Joon Yim, In Hee Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Chang Wook Kim, So Young Kwon, Sang Hoon Park, Myung Seok Lee, Soon Ho Um, Kwan Soo Byun
Entecavir 0.5 mg (ETV) is widely used among treatment-naïve chronic hepatitis B (CHB) patients. However, 10%-30% of patients show partial virologic response (PVR) to the drug. If the hepatitis B virus (HBV) continues to replicate, the underlying liver disease may progress. Herein, we compared the efficacy of switching to tenofovir disoproxil fumarate (TDF) with that of continuing ETV in CHB patients with PVR to ETV. This was an open-label randomized controlled trial including CHB patients who had been receiving 0...
May 17, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29761604/remaining-hepatocellular-carcinoma-risk-in-chronic-hepatitis-b-patients-receiving-entecavir-tenofovir-in-south-korea
#2
Jung Hwan Yu, Young-Joo Jin, Jin-Woo Lee, Don-Haeng Lee
BACKGROUND/AIM: We aimed to identify the incidence rate of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with entecavir or tenofovir in South Korea, and to identify predictors of HCC development in these patients. METHODS: Between January, 2007 and December, 2015, 582 CHB patients initially received entecavir (n=406, 69.8%) or tenofovir (n=176, 30.2%) for CHB. RESULTS: During a median follow-up of 57.1 months, HCC developed in 38 (6...
May 14, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29758335/normal-on-treatment-alt-during-antiviral-treatment-is-associated-with-a-lower-risk-of-hepatic-events-in-patients-with-chronic-hepatitis-b
#3
Grace Lai-Hung Wong, Henry Lik-Yuen Chan, Yee-Kit Tse, Terry Cheuk-Fung Yip, Kelvin Long-Yan Lam, Grace Chung-Yan Lui, Vincent Wai-Sun Wong
BACKGROUND AND AIMS: Recent studies reveal the rate of normal on-treatment alanine aminotransferase (ALT) appears different for different nucleos(t)ide analogues (NAs); yet its clinical significance is unclear. We aimed to evaluate the impact of normal on-treatment ALT during antiviral treatment with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB). METHODS: A territory-wide cohort of CHB patients who received ETV and/or TDF in 2005-2016 was identified...
May 11, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29753085/effects-of-virologic-response-to-treatment-on-short-and-long-term-outcomes-of-patients-with-chronic-hbv-infection-and-decompensated-cirrhosis
#4
Jeong Won Jang, Jong Young Choi, Young Seok Kim, Jeong-Ju Yoo, Hyun Young Woo, Sung Kyu Choi, Chung Hwan Jun, Chang Hyeong Lee, Joo Hyun Sohn, Won Young Tak, Yu Rim Lee, Kwang-Hyub Han
BACKGROUND & AIMS: Little is known about the effects of antiviral therapy on short- and long-term survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis. We aimed to determine whether a maintained virologic response (MVR, defined as persistent undetectable HBV DNA during therapy) associates with short-term (6-month) and long-term (6-120 months) survival of patients with decompensated cirrhosis. METHODS: We performed a 10-year observation analysis using data from the Epidemiology and Natural History of Liver Cirrhosis study of patients with decompensated liver cirrhosis in Korea...
May 9, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29752943/distinct-notch-signaling-expression-patterns-between-nucleoside-and-nucleotide-analogues-treatment-for-hepatitis-b-virus-infection
#5
Zijing Wang, Kazunori Kawaguchi, Masao Honda, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Shuichi Kaneko
Nucleos(t)ide analogues therapies are currently approved for the treatment of chronic hepatitis B virus (HBV) infection, which effectively suppress HBV replication and correlate with the anti-HBV-specific immune response. Notch signaling serves pleiotropic roles in the immune system that also contribute to virus-specific immunity. In this study, we assessed Notch signal-related gene expression after administrating nucleoside or nucleotide analogues to HBV-replicating cells and clinical liver tissues. We found distinct Notch signaling expression patterns under nucleos(t)ide analogues therapies, with high expression for nucleotide analogues (adefovir pivoxil or tenofovir disoproxil fumarate) and low expression for nucleoside analogues (lamivudine or entecavir) in the presence of HBV infection...
May 9, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29751272/overcoming-immune-tolerance-in-chronic-hepatitis-b-by-therapeutic-vaccination
#6
REVIEW
Claudia Dembek, Ulrike Protzer, Michael Roggendorf
The currently used nucleoside analogs (i.e. entecavir and tenofovir) with high barrier-to-resistance efficiently suppress viral replication, limit inflammation and reduce the sequelae of chronic hepatitis B, but cannot cure the disease and thus have to be applied long-term. Therapeutic vaccination as an approach to cure chronic hepatitis B has shown promising pre-clinical results, nevertheless the proof of its efficacy in clinical trials is still missing. This may be partially due to suboptimal vaccine design...
May 8, 2018: Current Opinion in Virology
https://www.readbyqxmd.com/read/29740207/development-of-tenofovir-disoproxil-fumarate-resistance-after-complete-viral-suppression-in-a-patient-with-treatment-na%C3%A3-ve-chronic-hepatitis-b-a-case-report-and-review-of-the-literature
#7
Woo Hee Cho, Hyun Jae Lee, Ki Bae Bang, Seok Bae Kim, Il Han Song
Tenofovir disoproxil fumarate (TDF) is a potent nucleotide analogue that is recommended as first-line therapy for patients with chronic hepatitis B. The results of a longitudinal study of TDF treatment demonstrated no development of resistance. We observed one treatment-naïve chronic hepatitis B (CHB) patient who developed TDF resistance after complete viral suppression during long-term TDF treatment. A 37-year-old HBeAg-positive man received TDF 300 mg/d for 43 mo. The hepatitis B virus (HBV) DNA titer was 8 log10 copies/mL at baseline and became undetectable at 16 mo after treatment...
May 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29735294/entecavir-or-tenofovir-monotherapy-prevents-hbv-recurrence-in-liver-transplant-recipients-a-5-year-follow-up-study-after-hepatitis-b-immunoglobulin-withdrawal
#8
Matteo A Manini, Gavin Whitehouse, Matthew Bruce, Matteo Passerini, Tiong Y Lim, Ivana Carey, Aisling Considine, Pietro Lampertico, Abid Suddle, Nigel Heaton, Michael Heneghan, Kosh Agarwal
BACKGROUND: Recent data suggest that oral third-generation nucleos(t)ide analogs (NA) monoprophylaxis following hepatitis B immunoglobulin (HBIg) withdrawal may be effective to prevent HBV reinfection after liver transplantation (LT). PATIENTS AND METHODS: Between 01/2010 and 03/2012, all HBV monoinfected and HBV/HDV co-infected LT patients followed in our centre withdrew HBIg ± NA and were commenced on either ETV or TDF as monotherapy. RESULTS: Seventy-seven patients were included in the study (55% TDF, 45% ETV)...
April 13, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29725560/fatal-fulminant-hepatitis-from-rituximab-induced-hepatitis-b-reactivation-in-a-patient-with-follicular-lymphoma-a-case-report-and-a-brief-review-of-literature
#9
Zarak H Khan, Kamran Ilyas, Haider Ghazanfar, Hamza H Khan, Qulsoom Hussain, Sahla Hammad, Ahmed Munir, Rizwan Asim
The objective of our study was to recognize hepatitis B reactivation as a complication of rituximab chemotherapy and to realize the importance of screening for prior Hepatitis B virus (HBV) exposure in all patients with hematologic malignancies who will receive rituximab as part of their therapy. Rituximab is a monoclonal antibody targeting CD 20 receptors on the membrane of B cells. In this case report, we described a 79-year-old man who presented to our department with nausea, fatigue, and jaundice. Two months ago, he had received the last dose of the chemotherapy regimen containing rituximab for follicular B cell lymphoma...
March 2, 2018: Curēus
https://www.readbyqxmd.com/read/29715359/chronic-hepatitis-b-infection-a-review
#10
REVIEW
Lydia S Y Tang, Emily Covert, Eleanor Wilson, Shyam Kottilil
Importance: More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer. Observations: Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and tenofovir alafenamide) suppress HBV DNA replication and improve liver inflammation and fibrosis...
May 1, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29714442/changes-of-serum-spd-1-levels-in-hbeag-positive-chronic-hepatitis-b-patients-with-entecavir-treatment-and-correlation-with-curative-effect
#11
Chunhua Bi, Deyu Huang, Jing Jiang, Yueping Jiang, Hui Wang, Cheng Bian, Zibin Tian
Background/aim: This study aimed to assess expression changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients with entecavir treatment and explore the correlation with the curative effect. Materials and methods: A total of 220 HBeAg-positive CHB patients and 207 healthy individuals were included. sPD-1 levels and virological and biochemical responses were assessed at baseline and at 12, 24, and 48 weeks in CHB patients after antiviral therapy. Results: sPD-1 levels in HBeAg-positive CHB patients before treatment were significantly lower than those of healthy controls...
April 30, 2018: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/29707081/efficacy-and-safety-of-entecavir-0-5-mg-in-treating-naive-chronic-hepatitis-b-virus-patients-in-egypt-five-years-of-real-life-experience
#12
Sahar Maklad, Ehab Mahfouz Reyad, Emad Adel William, Alaa Abouzeid
Background: The aim of the study was to evaluate the efficacy and safety of entecavir (ETV) among chronic hepatitis B (CHB) nucleos(t)ide-naive Egyptian patients. Methods: Forty-eight CHB patients on ETV were included. Males comprised 83.3% (40 cases), while females comprised 16.7% (eight cases). Minimum age was 19 years, while maximum age was 64 years. Hepatitis B envelope antigen (HBeAg)-negative cases were 60.4%. HBeAg-positive cases were 39.6%. Factors including sex, positive HBeAg, baseline hepatitis B virus (HBV) DNA level, baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were evaluated in terms of their predictive role in treatment response, which was defined as a serum HBV DNA decrease of < 10 IU/mL...
April 2018: Gastroenterology Research
https://www.readbyqxmd.com/read/29702120/chinese-herbal-extract-su-duxing-had-potent-inhibitory-effects-on-both-wild-type-and-entecavir-resistant-hepatitis-b-virus-hbv-in-vitro-and-effectively-suppressed-hbv-replication-in-mouse-model
#13
Yan Liu, Weiming Yao, Lanlan Si, Jun Hou, Jiabo Wang, Zhihui Xu, Weijie Li, Jianhong Chen, Ruisheng Li, Penggao Li, Lvping Bo, Xiaohe Xiao, Jinchu Lan, Dongping Xu
The present study aimed to investigate anti-HBV effect and major active compounds of Su-duxing, a medicine extracted from Chinese herbs. HBV-replicating cell lines HepG2.2.15 (wild-type) and HepG2. A64 (entecavir-resistant) were used for in vitro test. C57BL/6 mice infected by adeno-associated virus carrying 1.3 mer wild-type HBV genome were used for in vivo test. Inhibitory rates of Su-duxing (10 μg/mL) on HBV replicative intermediate and HBsAg levels were 75.1%, 51.0% in HepG2.2.15 cells and 65.2%, 42...
April 24, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29700765/platelets-increase-is-associated-with-improvement-of-liver-fibrosis-in-entecavir-treated-chronic-hepatitis-b-patients-with-significant-liver-fibrosis
#14
Lin Wang, Bingqiong Wang, Hong You, Xiaoning Wu, Jialing Zhou, Xiaojuan Ou, Jidong Jia
BACKGROUND AND AIM: Reduction of platelet count is often observed in chronic hepatitis B (CHB) patients with significant liver fibrosis. In this cohort study, we investigated whether platelets' increase after entecavir (ETV) therapy was associated with the improvement of liver fibrosis. METHODS: We collected the data of a cohort 82 CHB patients with paired liver biopsies before and after 78-week ETV therapy, and assessed the platelets' change following the treatment and further investigated the associated clinical factors with platelets' change...
April 26, 2018: Hepatology International
https://www.readbyqxmd.com/read/29697528/to-use-entecavir-tenofovir-disoproxil-fumarate-or-tenofovir-alafenamide-it-s-all-about-choosing-the-right-patient
#15
Sandeep Satsangi
No abstract text is available yet for this article.
June 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29696665/using-the-chronic-kidney-disease-guidelines-to-evaluate-the-renal-safety-of-tenofovir-disoproxil-fumarate-in-hepatitis-b-patients
#16
H J Tsai, Y W Chuang, S W Lee, C Y Wu, H Z Yeh, T Y Lee
BACKGROUND: Renal dysfunction remains an issue in tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) patients. AIM: To evaluate renal safety of TDF according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. METHODS: We retrospectively recruited CHB patients who received either TDF or entecavir (ETV) monotherapy from January 2008 to August 2015. After excluding confounding conditions, 253 patients who received TDF were randomly matched 1:2 with 506 patients who received ETV through the propensity scores, which consisted of age, gender, cirrhosis, chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR)...
April 25, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29696462/longitudinal-monitoring-of-liver-fibrosis-status-by-transient-elastography-in-chronic-hepatitis-b-patients-during-long-term-entecavir-treatment
#17
Sheng-Di Wu, Li-Li Liu, Ji-Lin Cheng, Yun Liu, Li-Sha Cheng, Si-Qi Wang, Wei Ma, Li-Ping Chen, Yu-Jen Tseng, Ji-Yao Wang, Xi-Zhong Shen, Wei Jiang
The correlation between improvement in longitudinal liver stiffness and fibrosis regression has not been properly evaluated during long-term antiviral therapy in chronic hepatitis B (CHB) patients. In this study, liver stiffness was serially performed by FibroScan® every 26 weeks in a prospective cohort of CHB patients receiving entecavir. Results were compared with liver biopsies at baseline and week 78. A total of 120 treatment-naïve CHB patients were analyzed, in which 54 (45%) patients had fibrosis regression at 78 weeks of antiviral therapy...
April 25, 2018: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/29679439/younger-age-and-language-barriers-are-associated-with-non-adherence-to-clinical-follow-up-in-hepatitis-b-treatment
#18
Heng Chi, Angie Japhary, Robert A de Man, Robert J de Knegt, Harry L A Janssen, Bettina E Hansen
We investigated the incidence and predictors of non-adherence towards clinic visits in chronic hepatitis B (CHB) patients on entecavir or tenofovir treatment. This was a retrospective study of CHB patients treated for at least 3 months in a tertiary referral hospital in The Netherlands. Lack of attendance in clinic visits was defined as a missed follow-up visit without notice. 338 patients (48% Caucasian, 37% Asian) were followed for a median of 3.5 years. During 1283 person-years, 183 scheduled follow-up visits were missed in 101 patients resulting in 0...
April 21, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29677098/update-treatment-for-hbv-infection-and-persistent-risk-for-hepatocellular-carcinoma-prospect-for-an-hbv-cure
#19
REVIEW
Joseph Yoo, Hie-Won Hann, Robert Coben, Mitchell Conn, Anthony J DiMarino
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence, epidemiology, and hepatocarcinogenesis have been elucidated. Globally, hepatitis B virus (HBV) is still responsible for the majority of hepatocellular carcinoma (HCC). HCC is the sixth-most common cancer in the world and the second-most common cancer death. The ultimate goal of treating HBV infection is the prevention of HCC. Fortunately, anti-HBV treatment with nucleos(t)ide analogues (NAs), which began with lamivudine in 1998, has resulted in remarkable improvements in the survival of patients with chronic hepatitis B and a reduced incidence of HCC...
April 20, 2018: Diseases (Basel)
https://www.readbyqxmd.com/read/29662321/serum-hepatitis-b-core-antibody-levels-predict-hbeag-seroconversion-in-chronic-hepatitis-b-patients-with-high-viral-load-treated-with-nucleos-t-ide-analogs
#20
Shaohang Cai, Zhandong Li, Tao Yu, Muye Xia, Jie Peng
Background: Patients with chronic hepatitis B virus (HBV) infection who are hepatitis B virus e antigen (HBeAg) positive are increasingly being treated with nucleos(t)ide analogs (NUCs). However, the predictive value of serum hepatitis B virus core antibody (HBcAb) levels for HBeAg seroconversion among patients with high viral load remains unclear. Methods: This study consisted of 74 patients with high viral load (HBV DNA >1 × 107 copies/mL) enrolled in a multicenter, randomized, controlled trial, treated with lamivudine and adefovir (N = 32) or entecavir (N = 42) for up to 96 weeks...
2018: Infection and Drug Resistance
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"